U
AEGR

UBS’s Aegerion Pharmaceuticals AEGR Stock Holding History

UBS’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$83K Sell
2,500
-100
-4% -$3.1K ﹤0.01% 6225
2014
Q2 		$83K Hold
2,600
– – ﹤0.01% 6177
2014
Q1 		$120K Sell
2,600
-6,000
-70% -$352K ﹤0.01% 5774
2013
Q4 		$610K Sell
8,600
-10,300
-54% -$788K ﹤0.01% 4105
2013
Q3 		$1.62M Buy
18,900
+6,800
+56% +$576K ﹤0.01% 2818
2013
Q2 		$766K Buy
+12,100
New +$642K ﹤0.01% 3616

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's AEGR Position: Q3 2014 in Review

UBS increased its Aegerion Pharmaceuticals (AEGR) stake by 8.1% in Q3 2014, buying an estimated $9.93K and bringing the position to 4,262 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #5556.

UBS first reported a position in AEGR in Q2 2013 and has held it in 6 quarters since. The position peaked at $2.33M in Q3 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q3 2014.

  • UBS held 4,262 shares of Aegerion Pharmaceuticals worth $142K as of Q3 2014.
  • UBS bought 320 Aegerion Pharmaceuticals shares in Q3 2014, an estimated $9.93K.
  • Aegerion Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5556 holding.
  • UBS first reported a position in Aegerion Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Aegerion Pharmaceuticals position peaked at $2.33M in Q3 2013.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.